Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MCRB Stock 12 Month Forecast
Average Price Target
$5.50
▲(674.65% Upside)
| Highest Price Target$10.00 | Average Price Target$5.50 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
Reiterated
03/14/25
TD Cowen
Reiterated
03/13/25
Canaccord Genuity
Reiterated
03/13/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Seres Therapeutics downgraded to Underweight from Neutral at JPMorganSeres Therapeutics downgraded to Underweight from Neutral at JPMorgan
Chardan Capital
$1.25
Buy
76.06%
Upside
Reiterated
09/12/24
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (NASDAQ: MCRB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Exact Sciences (NASDAQ: EXAS)
Goldman Sachs
$1.1
Sell
54.93%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
03/14/25
TD Cowen
Reiterated
03/13/25
Canaccord Genuity
Reiterated
03/13/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Seres Therapeutics downgraded to Underweight from Neutral at JPMorganSeres Therapeutics downgraded to Underweight from Neutral at JPMorgan
Chardan Capital
$1.25
Buy
76.06%
Upside
Reiterated
09/12/24
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (NASDAQ: MCRB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Exact Sciences (NASDAQ: EXAS)
Goldman Sachs
$1.1
Sell
54.93%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
MCRB Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Mar 25
Strong Buy
5
2
2
2
3
Buy
3
3
1
2
2
Hold
3
2
1
0
1
Sell
2
1
1
0
0
Strong Sell
0
0
0
0
0
total
13
8
5
4
6
Each month's total comprises the sum of three months' worth of ratings.
MCRB Financial Forecast
MCRB Stock Forecast FAQ
What is MCRB’s average 12-month price target, according to analysts?
Based on analyst ratings, Seres Therapeutics’s 12-month average price target is $5.50.
What is MCRB’s upside potential, based on the analysts’ average price target?
Seres Therapeutics has 674.65% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MCRB a Buy, Sell or Hold?
Seres Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Seres Therapeutics’s price target?
The average price target for Seres Therapeutics is $5.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 674.65% Increase from the current price of $0.71.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 674.65% Increase from the current price of $0.71.
What do analysts say about Seres Therapeutics?
Seres Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of MCRB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.